Cargando…
Treatment With a Three-Drug Regimen for Pulmonary Tuberculosis Based on Rapid Molecular Detection of Isoniazid Resistance: A Noninferiority Randomized Trial (FAST-TB)
BACKGROUND: The rationale behind the use of ethambutol in the standard tuberculosis treatment is to prevent the emergence of resistance to rifampicin in case of primary resistance to isoniazid. We evaluated whether early detection of isoniazid resistance using molecular testing allows the use an eth...
Autores principales: | De Castro, N, Mechaï, F, Bachelet, D, Canestri, A, Joly, V, Vandenhende, M, Boutoille, D, Kerjouan, M, Veziris, N, Molina, J M, Grall, N, Tattevin, P, Laouénan, C, Yazdanpanah, Y |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356674/ https://www.ncbi.nlm.nih.gov/pubmed/35949399 http://dx.doi.org/10.1093/ofid/ofac353 |
Ejemplares similares
-
Correction to: Treatment With a Three-Drug Regimen for Pulmonary Tuberculosis Based on Rapid Molecular Detection of Isoniazid Resistance: A Noninferiority Randomized Trial (FAST-TB)
Publicado: (2022) -
Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the
endTB Cohort( )
por: Hewison, Catherine, et al.
Publicado: (2022) -
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial
por: Llibre, Josep M, et al.
Publicado: (2022) -
Effect of Gender on Clinical Presentation of Tuberculosis (TB) and Age-Specific Risk of TB, and TB-Human Immunodeficiency Virus Coinfection
por: Humayun, Maheen, et al.
Publicado: (2022) -
Agreement Between Measures of Adherence to Isoniazid Preventive Therapy Among People With HIV in Uganda
por: Forman, Leah S, et al.
Publicado: (2022)